* If you want to update the article please login/register
Introduction The dosimetric characteristics of radiotherapy have an immediate effect on the host immune system during chemoradiotherapy in locally advanced non-small cell lung cancer. However, a substantial number of patients are still immunosuppressed with delayed lymphopenia even after CRT. Therefore, we wanted to find clinical and dose-volumetric predictors of delayed lymphopenia after CRT in locally advanced NSCLC. NSCLC patients with locally advanced NSCLC who received definitive CRT from January 2012 to August 2020 were retrospectively reviewed 272 patients with locally advanced NSCLC with officially registered CRT from January 2012 to August 2020. Grade III/IV lymphopenia syndromes were classified as grade III/IV lymphopenia during or 4-12 weeks after CRT completion, accounting for 84% and 10% of cases, respectively. Conclusions Multivariate investigation showed that patients with delayed lymphopenia were associated with decreased overall survival and progression-free survival. Conclusions We looked at the prognostic significance of delayed lymphopenia and established clinico-dosimetric variables to predict delayed lymphopenia in this research.
Source link: https://doi.org/10.3389/fonc.2022.891221
Objectives This paper aims to identify risk factors for predicting fingolimod-induced lymphopenia in MS by regular hematological testing. The findings of 41 MS patients with marked lymphopenia were reported in 12 patients within one year. In the lymphopenia group than in the non-lymphopenia group, there was a more consistent history of therapy with any interferon-beta and lower median ALC. Conclusions Low baseline ALC and treatment history with any interferon-beta were risk factors for fingolimod-induced lymphopenia, which perhaps predicted from ALC on day 2.
Source link: https://doi.org/10.1177/2055217318759692
Introduction Lymphopenia is a well-known adverse event of dimethyl fumarate, and patients with persistent prolonged lymphopenia are prone to treatment discontinuation. We retrospectively investigated the effect of absolute lymphocyte count monitoring frequency on lym-phopenia detection as a result of the COVID-19 pandemic burden on healthcare clinics. Methods Samples from patients participating in phase 3 trials and the extension study were retrospectively reviewed using 3-month or 6-month intervals. Using Kaplan-Meier methods, the first lymphopenia event and first severe lymphopenia case were projected. Patients with persistent prolonged lymphopenia in three months and six months were found to be similar.
Source link: https://doi.org/10.1136/jnnp-2022-abn2.181
Background Dimethyl fumarate is a disease-modifying drug used to treat Multiple Sclerosis. Overall, 16 people with MS had persistent moderate lymphopenia, while 5 had persistent lymphopenia, and 5 had persistent severe lymphopenia. Conclusion Persistent moderate lymphopenia is particularly prevalent among people on DMF. Following DMF in people with lymphopenia who persistently lymphopenia, more detailed data is needed for both risk/benefit of maintaining DMF and DMT sequencing following DMF in people with lymphopenia.
Source link: https://doi.org/10.1136/jnnp-2022-abn2.198
A review of clinical observational studies and autopsy results in English and Chinese languages was done to answer this issue, as well as a search of published clinical trials. Peripheral lymphopenia affecting CD4 and CD8 T cells was a striking sign of severe COVID-19 in comparison to non-severe disease. According to autopsy results, T cells were ingrained into organs, particularly the lung. In patients with severe COVID-19, SARS-CoV-2 infection disrupts T cell circulation. Measuring T cell metabolism during COVID-19 will help with clinical risk-stratification of hospitalized patients and can help identify those who will benefit the most from treatments that target T cells.
Source link: https://doi.org/10.1093/immadv/ltab015
Dimethyl fumarate, a commonly used first-line immunomodulatory drug used for the treatment of relapsing-remitting multiple sclerosis. We conducted a prospective review of 323 patients treated DMF in our NHS Lothian MS clinic in Edinburgh, Scotland, shortly after the drug was introduced in 2014. Both increased the risk of devel-oping grade 2 lymphopenia as a result of older age and lower baseline absolute lymphocyte count, with the former also increasing the risk of severe, grade 3 lymphopenia. The decline in ALC occurs within the first 6 months of DMF therapy, and after this point, it does not declines but does not appear to increase. Clinicians will be able to make more informed decisions when choosing a drug to start a patient with multiple sclerosis by knowing the risk factors for DMF-induced lymphopenia.
Source link: https://doi.org/10.1136/jnnp-2022-abn.52
Casp8 E385/u0394 cells were expectedly resistant to Fas-induced apoptosis, according to affective TNF-mediated apoptosis, but Casp8E385/u0394E385 cells, which were labelled as stubborn to Fas-induced necroptosis, but Casp8 E385/u0394E385 cells were believed to be susceptible to necroptosis More importantly, CASP8 alerted cells to RIPK3-MLKL-dependent necroptosis by promoting complex II formation and RIPK1-RIPK3 activation. Both Casp8 and Casp8 mice with autoimmune lymphoproliferative syndrome developed transplantable lymphomyelitis in contrast to the Casp8 u2212/u2212 mice, but not by a kinase dead mutation, which was not caused by the Casp8/u2312/u2212 mice.
Source link: https://doi.org/10.1038/s41418-022-00938-9
This study was intended to see if persistent lymphopenia existed on the seventh day after the diagnosis of COVID-19 predicts ARDs. METHODS: A retrospective cohort analysis of 125 patients with COVID-19 who migrated to a government-designated medical center between January 14, 2020, and March 20, 2020. Following the diagnosis of COVID-19, complete blood cell counts were obtained on the day 0th, 3rd, and 7th. Patients with persistent lymphopenia were found to be independently linked to ARDs on the third and seventh day, albeit with non-ARDS. CONCLUSION: Following the declaration of COVID-19 research, the symptoms indicated persistent lymphopenia on the seventh day, and it may be a point for immunostimulation of COVID-19 ARDS.
Source link: https://doi.org/10.21203/rs.3.rs-66910/v1
To find BM dosimetric parameters of lymphopenia in patients with esophageal squamous cell carcinoma, we analyzed the connection between peripheral blood lymphocytes, exposed sternum and vertebra body BM, and overall survival to find BM dosimetric parameters of lymphopenia. Conclusions: A small amount of sternum BM irradiated by more than 20 Gy could have a direct effect on peripheral blood lymphocytes. The patients' v20 of sternum BM and V50 of vertebra body BM were related to the patients' OS, and the ALC2's level could influence the patients' u2019 outcomes. The 218 patients with ALC2 0. 8 0. 9. 0/L had a significantly longer OS than those with ALC2 0. 6 0. 10 9 /L, according to the Cox regression results, with ALC2 0. 8 0. 8 0. 9 /L. Conclusion: The relative amount of sternum BM irradiated by more than 20 Gy in patients with ESCC was associated with lymphocytes.
Source link: https://doi.org/10.21203/rs.3.rs-66132/v1
* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions